Updates in Frontline Treatment of Metastatic Liver Cancer

home / news-network / frontline-treatment-of-metastatic-liver-cancer

EP. 1: Overview and Diagnosis of HCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 2: Initiation of Systemic Therapy for mHCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 3: IMbrave150 Trial: Frontline Treatment of Advanced HCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 4: Safety of PD-L1 Inhibitors in mHCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 5: Role of VEGF TKIs for Treatment of HCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 6: ASCO 2020: HIMALAYA Trial for Advanced HCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 7: ASCO 2020 Data for Treatment of Advanced HCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 8: mHCC: Influence of PD-L1 Inhibitors on Second-Line Therapy

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

EP. 9: Future Directions for mHCC

By Richard S. Finn, MD, UCLA Health
Richard Kim, MD, Moffitt Cancer Center

July 24th 2020

Latest Conference Coverage

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512